Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on G-CSF

Posted by Matt Breese on Jul 23, 2016

Find me on:

According to our recent payer coverage analysis for G-CSF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for G-CSF products shows some differences in coverage across major payer channels. Commercial formularies are the least restricted, with 90% of lives covered overall. Medicare Part D plans, however, restrict access for 81% of U.S. lives.


Source: MMIT data as of Q3 2016

Trends: One trend is the expanded utilization of G-CSF products following the biosimilar debut. While most research derives from Europe, many experts believe the same trend will occur in the United States, according to IMS. This market represents an enticing opportunityfor emerging biosimilar pharmaceutical manufacturers as the overall revenue in the space grows.

To read the full Reality Check on G-CSF treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check


Topics: Specialty, Market Access, Payer, Branding & Marketing